• J. Neurochem. 2017 May 1; 141 (3): 473-474.

Abstract'CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats' by Hu X.-M., Liu Y.-N., Zhang H.-L., Cao S.-B., Zhang T., Chen L.-P. and Shen W. The above article from Journal of Neurochemistry, published online on 26 January 2015 and in volume 132, issue 4, pages 452-463 (available through www.onlinelibrary.wiley.com), and its subsequent Corrigendum, published online on 5 February 2015 and in volume 132, issue 4, p. 487, have been retracted by agreement between the Journal's Editor-in-Chief, Jörg Schulz, corresponding author Wen Shen on behalf of the authors, and John Wiley & Sons Ltd. The retraction has been agreed as the same GFAP immunostaining image was used to represent different experimental conditions in two different publications (Shen et al. [2014] in the Journal of Neuroinflammation and Hu et al. [2015] in the Journal of Neurochemistry), with apparent brightness changes between the images. Shen et al. (2014) show in the outer right panel of Figure 4a, as well as in Fig. 8A for the GFAP/sham condition, a GFAP immunostaining after treatment with TCI + Fluorocitrate. The same image, at a lower intensity, is used in Hu et al. (2015) in the first panel of figure 5b as a sham control. The shape of the tissue margins of the spinal cord section as well as several landmark epitopes that point towards identical images are encircled: Shen et al. 2014 Figure 4a Hu et al. 2015 Figure 5b Shen et al. 2014 Figure 8a The authors confirmed that 'The research published in JNC sequentially builds on our previous study published in Journal of Neuroinflammation, as we have mentioned in the discussion. So, at the beginning, we performed these experiments and wrote these two manuscripts together,' whereas the statements in the Hu et al. paper, 'The testing procedure was performed according to previously standardized protocols (Hargreaves et al. 1988) and our published report (Shen et al. 2014) … confirmed our previous report (Shen et al. 2014)' imply that the Hu et al. study was a follow-up based on a new original data set. The authors were given the opportunity to respond and to provide the original raw images. Several Sham group GFAP immunostainings were sent. However, the reliability of the data that was presented in the publication could not be confirmed and the paper is therefore being retracted. A corrigendum related to a different problem with data representation that was previously issued for this paper is also being retracted (Hu et al. 2015, Corrigendum). References Hu X. M., Liu Y. N., Zhang H. L., Cao S. B., Zhang T., Chen L. P. and Shen W. (2015a) CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKS-mediated neuroinflammation in bonce cancer rats. J. Neurochem. 132, 452-463. doi:10.1111/jnc.12985. Hu X. M., Liu Y. N., Zhang H. L., Cao S. B., Zhang T., Chen L. P. and Shen W. (2015b) Corrigendum. J. Neurochem. 132, 487. doi:10.1111/jnc.13054. Shen W., Hu X. M., Liu Y. N., Han Y., Chen L. P., Wang C. C. and Song C. (2014) CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord. J. Neuroinflammation 11, 75. doi:10.1186/1742-2094-11-75.© 2017 International Society for Neurochemistry.

6 keywords...

hide…